<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="49603">Lapatinib</z:chebi> is a clinically important component of the treatment for HER2-positive metastatic <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and has an acceptable safety profile </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="49603">Lapatinib</z:chebi>-associated Hy's Law cases have been characterized using human leukocyte antigen (HLA) DQA1*02:01/DRB1*07:01 and <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> UGT1A1*28/*28 genotypes </plain></SENT>
<SENT sid="2" pm="."><plain>The HLA-positive cases had higher alanine aminotransferase (ALT) elevation, whereas the HLA-negative cases had a higher incidence of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The findings of our study, which extend this HLA association to <z:chebi fb="0" ids="49603">lapatinib</z:chebi>-associated serious liver injury, emphasize the importance of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> in the interpretation of Hy's Law and may lead to methods for enhancing patient safety </plain></SENT>
</text></document>